A new testing method uses omics markers to reveal the trajectory of recovery from trauma, enabling more-tailored care. The approach shows that organ failure and mortality can be predicted with high accuracy using biological signals found in blood.
A new study from CU Anschutz researchers found that regular physical activity can significantly lower post-ablation atrial fibrillation recurrence risk. Adults who engaged in moderate exercise for 30 minutes three times a week had markedly lower rates of AF recurrence compared to those who were less active.
Research at the University of Colorado Anschutz Linda Crnic Institute found significant alterations in liver metabolism among individuals with Down syndrome, including elevated bile acids and biomarkers of liver dysfunction. The study suggests that dietary interventions may help improve health outcomes.
Researchers discovered a link between increasing biomarker levels and cognitive decline, with a potential repurposed drug slowing damage. The study found exponential increases in UCH-L1 and GFAP levels with age, suggesting underlying neuroinflammation may contribute to Alzheimer’s disease.
A new study published in JAMA Health Forum estimates that ending federal funding for Housing First programs would result in 44,590 additional people experiencing homelessness within a year, a roughly 5% increase from 2024 levels. This could push tens of thousands of people back into homelessness almost overnight.
A multi-site study led by CU Anschutz researchers found that people with cystic fibrosis who start triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many daily lung treatments while maintaining good health for years. The study showed a steady decline in the use of chronic respiratory therapies, including hype...
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.